Vyriad, a gene therapy company based in Rochester, has raised $85 million to support its new VV-169 cancer treatment which ...
Understand why testing must evolve beyond deterministic checks to assess fairness, accountability, resilience and ...
The first healthy volunteers have been dosed in an early clinical trial testing NRG5051, a disease-modifying therapy for ALS ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback